Section
Long-term data from lung cancer screening reveal centrilobular emphysema progression strongly associates with coronary artery calcification worsening, highlighting systemic vascular implications of this emphysema subtype.
This population-wide study demonstrates that parathyroidectomy in primary hyperparathyroidism reduces major adverse cardiovascular events risk, particularly in patients with higher serum calcium levels.
Early weight loss after impaired glucose tolerance diagnosis is linked to markedly reduced long-term risk of cardiovascular events and death, underscoring the importance of early lifestyle interventions in prediabetes management.
This study reveals that risk factor associations for subsequent coronary heart disease (CHD) events are systematically attenuated due to index event bias, challenging their clinical interpretation in secondary prevention and emphasizing the
This meta-analysis of 17 Phase 3 RCTs reveals that BTK inhibitors, primarily ibrutinib, increase the risk of non-fatal ischemic cardiovascular events in patients with B-cell malignancies, highlighting important safety considerations.
Clonal hematopoiesis (CHIP) significantly associates with increased silent brain lesions and progressive cognitive decline in atrial fibrillation patients, highlighting a novel neurovascular risk factor with implications for patient managem
Textbook outcome—a composite measure of survival without complications or prolonged hospitalization—effectively distinguishes hospital performance and predicts 180-day mortality and readmission following elective adult cardiac surgery.
This study reveals that the characteristics of carotid plaque calcifications on CTA scans correlate with stroke symptoms beyond traditional stenosis severity, offering improved risk stratification for carotid artery disease.
This article reviews improvements in heart failure management and outcomes in Japan between 2013 and 2019-21, highlighting increased guideline-based therapy use and enhanced post-discharge care leading to reduced mortality and readmission r
This article explores how myeloid cell expansion drives right ventricular dysfunction in HFpEF through sterile inflammation, highlighting translational insights from murine models and human studies.
Bempedoic acid reduces the risk of major adverse limb and cardiovascular events in statin-intolerant patients with peripheral artery disease, illustrating its potential to enhance vascular risk management.
Single-cell multi-omics profiling reveals novel immune signatures linked to coronary artery disease and cardiovascular outcomes, independent of traditional inflammatory markers, offering new avenues for risk stratification and personalized
The TARTAN-HF trial demonstrated that targeted natriuretic peptide screening in high-risk diabetic patients uncovers a high prevalence of undiagnosed heart failure, mainly HFpEF, enabling earlier treatment initiation and improved clinical c
The PREVUE-VALVE Study demonstrates that AI-ECG models developed in hospital settings show reduced diagnostic accuracy when applied to community populations with lower disease prevalence and milder structural heart disease, underscoring the
In the SELECT trial, semaglutide significantly lowered hsCRP levels and major cardiovascular events in patients with established atherosclerotic cardiovascular disease and overweight or obesity, suggesting inflammation reduction as a possib
Metrnl reduces platelet activation and thrombus formation by promoting CD36 degradation, offering a promising therapeutic strategy for thrombotic diseases including acute myocardial infarction without increasing bleeding risk.
In type 2 diabetes patients with coronary artery disease, suPAR levels remain unchanged despite treatment and independently predict adverse cardiovascular events beyond hs-CRP, highlighting suPAR’s potential in identifying treatment-r
This article reviews the prognostic role of left atrial dysfunction in transthyretin amyloid cardiomyopathy and evaluates vutrisiran’s impact on atrial function and clinical outcomes based on a secondary analysis of the HELIOS-B phase 3 tri
This study identifies RUNX1-mediated endothelial-to-mesenchymal transition as a key driver of myocardial fibrosis and remodeling in LMNA cardiomyopathy, highlighting potential therapeutic avenues targeting endothelial RUNX1 signaling.
This review synthesizes evidence on colchicine’s efficacy in secondary stroke prevention, emphasizing the impact of concomitant atherosclerosis on outcomes from the CONVINCE trial and meta-analyses.
